- Home
- PSF vs WHWK Comparison
PSF vs WHWK Comparison
Compare PSF & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSF | WHWK |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.8M | 213.2M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PSF | WHWK |
|---|---|---|
| Price | $18.02 | $3.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.71 |
| AVG Volume (30 Days) | 66.0K | ★ 306.8K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | ★ 86.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,145,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.80 | $1.97 |
| 52 Week High | $21.06 | $5.50 |
Technical Indicators
Market Signals| Indicator | PSF | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 33.48 | 21.77 |
| Support Level | $17.80 | $2.46 |
| Resistance Level | $20.02 | $3.88 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 28.57 | 2.76 |
Price Performance
Historical ComparisonAbout PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.